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Abstract
Introduction—Despite the effectiveness of oral PrEP for HIV prevention, knowledge and uptake 
of this new prevention intervention over time has not been fully studied. Using NHBS data from 
two urban areas highly impacted by HIV, we examined awareness, use, and willingness to use 
daily oral PrEP and factors associated with willingness to take oral PrEP among MSM over time.
Methods—MSM from Washington, DC and Miami, FL were recruited in 2011 and 2014 using 
venue-based sampling. Participants completed behavioral surveys and HIV testing. Awareness, 
use, and willingness to use oral PrEP were examined. Demographic and behavioral correlates of 
being “very likely” to use PrEP in 2011 and 2014 were assessed.
Results—PrEP awareness increased from 2011 to 2014 in both cities (DC: 39.1% to 
73.8%;Miami: 19.4% to 41.2%), but use remained low in 2014 (DC: 7.7%;Miami: 1.4%). Being 
very likely to use PrEP decreased over time in DC (61% to 48%), but increased in Miami (48% to 
60%). In DC, minority race was associated with increased odds of being very likely to use PrEP, 
while a reduced odds of being very likely to use PrEP was observed for MSM with 1 or 2-5 
partners versus having 6+ partners. In Miami, a higher proportion of White versus Hispanic MSM 
reported being very likely to use PrEP in 2011, but this observation was reversed in 2014.
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Conclusion—Geographic differences in awareness, use, and willingness to use PrEP indicate 
that innovative strategies are needed to educate MSM about this effective prevention strategy.
Keywords
men who have sex with men; pre-exposure prophylaxis; willingness to use PrEP; National HIV 
Behavioral Surveillance
Introduction
In the United States (U.S.), men who have sex with men (MSM) continue to be 
disproportionately affected by HIV. While MSM represent only 3-10% of the U.S. 
population,1 they account for nearly 60% of new HIV infections.2 Nationally, young, Black, 
and Hispanic MSM represent a majority of new infections,3,4 and these trends persist at the 
local level in Washington, DC and Miami-Dade County, Florida, two racially and ethnically 
diverse HIV epicenters.5,6
In 2010, data from one of the first studies on the efficacy of HIV antiretroviral medication as 
HIV prevention provided evidence for the use of pre-exposure prophylaxis (PrEP) for HIV 
prevention among men who have sex with men.7 Based on additional evidence from 
subsequent trials8-10, the U.S. Food and Drug Administration (FDA) approved Truvada 
(Tenofovir disoproxil/emtricitabine) for use as once-daily oral PrEP in 201211, and the 
Centers for Disease Control and Prevention (CDC) released clinical recommendations for 
the use of PrEP in 2014.12 Although there were initial concerns that PrEP would be 
ineffective in real-world use due to issues with adherence and risk compensation, PrEP 
studies outside of clinical trial populations have shown promising results among those with 
higher levels of adherence and those who remained on the intervention, compared to those 
who discontinued taking PrEP.13 Open-label demonstration studies in the U.S. and England 
have shown high levels of protection against HIV.14,15 Volk et al. found no new HIV 
infections among PrEP users attending a clinic in San Francisco, CA, over 388 person-years 
of follow-up, despite high rates of sexually transmitted infections (STIs) and a reported 
decrease in condom use among a subset of participants.16
Despite these promising findings, initial uptake of PrEP outside of research and 
demonstration projects has been slow. An analysis of U.S. pharmacy data from 2012 to 
2014, found 3,253 unique individuals, 68% of whom were male, had used PrEP.17 More 
recent studies, however, have found significant increases in PrEP use, as reported by urban 
and internet-based samples of MSM. Between 2013 and 2015, PrEP use among MSM in 
New York City increased from 2.1% to 14.8%.18 A national internet sample of MSM found 
significant increases in self-reported PrEP use in MSM in several U.S. cities from 
2012-2015.19 A study of high-risk MSM in Seattle, WA, found the largest reported increase 
in PrEP use from 5% to 31% between 2012 and 2015, with 23% currently taking PrEP.20 
While these studies reveal increases in PrEP use, there is still much work to be done in light 
of the estimated 492,000 MSM eligible for PrEP in the US.21
Understanding knowledge of and willingness to use PrEP among MSM at high-risk for HIV 
is an important step to increasing PrEP utilization. To date, few studies have examined 
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willingness to use PrEP among MSM. Prior to FDA approval in 2012, Mimiaga et al. found 
that while knowledge of PrEP was low among MSM in Boston, there was a high level of 
interest in using PrEP.22 Among MSM in Denver, between 2008 and 2014 awareness 
significantly increased over time, but less than 50% had ever heard of PrEP in 2014,and 
willingness to use PrEP did not significantly change over time. 23 A recent study of 206 
highly sexually active MSM in New York City, between 2011 and 2013, also found no 
significant change in willingness, despite a significant increase in awareness of PrEP, from 
53% to 72%.24 In a national study among internet-recruited MSM, a slight increase in self-
reported willingness to use PrEP was found between 2012 and 2015,19 increasing from 
39.3% to 49.6%.
Given the increasing rates of HIV among MSM and the need for increased prevention 
efforts, it is imperative that we better understand the awareness and uptake of PrEP in 
communities that have been highly impacted by HIV in order to target PrEP-related 
prevention programming. This study examines changes in awareness of PrEP, self-reported 
use and degree of willingness to use PrEP among a community-recruited sample of sexually 
active MSM from 2011 to 2014 in two urban areas highly impacted by HIV—Washington, 
DC and Miami-Dade County, FL. Demographic characteristics, and sexual and substance 
use behaviors were assessed as correlates of self-reported willingness to use PrEP in both 
2011 and 2014.
Methods
Washington, DC and Miami-Dade County, FL, two urban centers with high HIV prevalence, 
were funded by the CDC through the Enhanced Comprehensive HIV Prevention Planning 
Initiative (ECHPP) to maximize uptake of high impact HIV prevention interventions.25 As a 
part of this initiative, the Centers for AIDS Research in Washington, DC and Miami-Dade 
County, FL proposed a collaboration to examine PrEP uptake through the role of both the 
provider and potential consumers.26,27 In order to address the latter aim, two measures were 
added to the supplemental local NHBS questions in both cities to assess willingness to use 
PrEP and perceptions of condom use behavior if using PrEP.
Data from the CDC National HIV Behavioral Surveillance (NHBS) system conducted in 
Washington, DC and Miami-Dade County, FL during the 2011 (MSM-3) and 2014 (MSM-4) 
data collection cycles focusing on MSM were analyzed. The NHBS system began in 2003 
and during 2011 and 2014, the years of data collection used in this analysis, NHBS was 
conducted in 20 cities. NHBS is a serial, cross-sectional behavioral surveillance community 
survey that is conducted among three populations at highest risk for HIV: MSM, persons 
who use injection drugs, and heterosexuals at elevated risk for HIV. Recruitment for the 
MSM cycles in this analysis were completed in 2011 and 2014, and interviews were 
conducted among men recruited using venue-based time-space sampling (VBS).28 Briefly, 
in each city, a sampling frame of all eligible venues was generated using formative research 
that included all potential public venues from which MSM could be recruited. Eligible 
venues were those at which at least 50% of the male attendees were MSM (assessed by 
formative research, including street intercept interviews). Venues and days and times of the 
week were randomly selected for community-based recruitment on a monthly basis.
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Study eligibility included being male assigned at birth and currently identifying as male, 18 
years of age or older, having had sex with a man in the past year, and living in the 
metropolitan statistical area in which the study was conducted. Men were approached and 
screened by study staff to ascertain eligibility to participate in the survey, and eligible 
individuals were consented and completed a face-to-face interviewer-administered 
behavioral survey using a handheld or tablet computer. Questions included demographic 
characteristics, sexual and drug use risk behaviors, HIV testing behaviors, and utilization of 
HIV prevention programs. All participants were offered rapid HIV-testing; self-reported and 
preliminary HIV-positive individuals were confirmed using Western Blot and were 
immediately referred to care. Individuals received incentives for completing the survey ($25 
in Washington, DC and $25 in Miami-Dade County, FL) and for being tested for HIV ($10 
in Washington, DC and $25 in Miami-Dade County, FL).
Measures
To assess awareness and use of antiretroviral medications (ARVs) as HIV prevention, 
participants were asked whether they had “ever heard of people who do not have HIV taking 
anti-HIV medicines, to keep from getting HIV?” and if they had used PrEP in the last 12 
months. Participants who reported any PrEP use in the last 12 months were also asked where 
they received ARVs (doctor or health care provider, sex partner, friend or relative, internet, 
or some other location).
To assess willingness to use PrEP, participants were presented with a scenario in which daily 
oral PrEP was available for free or covered by their health insurance and asked how likely 
they would be to take it with the following response options: “very likely”, “somewhat 
likely”, or “not at all likely”. For this analysis, participants responding very likely were 
considered to be willing to use PrEP, while those responding as being somewhat or not at all 
likely to use PrEP were coded as not being willing to use PrEP. An additional follow-up 
question was asked regarding whether participants strongly agreed, agreed, disagreed or 
strongly disagreed with the statement “If I am taking HIV medicines to prevent HIV 
infection, I will no longer need to use condoms or practice safer sex.” For this analysis, 
responses were dichotomized as “strongly agree/agree” and “strongly disagree/disagree.”
Data Analysis
All analyses were stratified by city. Demographic characteristics, sexual risk and drug use 
behaviors, and HIV testing behaviors, as well as reported awareness, use, and willingness to 
use PrEP were examined in both 2011 and 2014. For categorical variables, frequencies were 
reported by cycle year, and χ2 or Fisher's exact tests were used to assess differences in the 
distribution of variables across cycle years. Logistic regression was used to generate 
unadjusted and adjusted odds ratios (ORs and aORs, respectively) and 95% confidence 
intervals (CI) to assess correlates of being “very likely” vs. “somewhat/not at all likely” to 
use PrEP. In order to produce comparable models across cities, variables that attained a 
p<0.05 statistical significance in univariate analyses in either city were included in each 
city's model.
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In 2011 and 2014, 503 and 510 eligible MSM completed surveys in Washington, DC and 
511 and 534 completed surveys in Miami-Dade County, respectively. For this analysis, the 
sample was limited to participants who responded to locally-developed questions on 
willingness to use PrEP. Self-reported HIV-positive individuals were also excluded because 
this analysis focuses on use of and willingness to use PrEP for HIV prevention. Because 
HIV rapid test results were given after the survey was finished, individuals who were newly 
identified as preliminary positive were included in this analysis as their responses were 
captured prior to disclosure of results. Therefore, in both cities, a total of 602 confirmed 
HIV-negative or newly diagnosed MSM were included in 2011 (n=323 in Washington, D.C. 
and n=279 in Miami-Dade County) and 774 were included in 2014 (n=313 in Washington, 
DC and n=431 in Miami-Dade County). All analyses were completed using SAS version 9.3 
(Cary, NC).
Results
As seen in Table 1, in Washington, DC a smaller proportion of MSM in 2011 versus 2014 
reported at least some college education (83.9% vs. 91.4%, p=0.004), having received an 
HIV test in the last 12 months (69.7% vs. 77.3%, p=0.03) and condomless anal sex at last 
sex (33.4% vs. 42.8%, respectively, p=0.02). In Miami-Dade County, there were several 
significant demographic differences between MSM respondents from 2011 and 2014. In 
2014 compared to 2011, a lower proportion of MSM were 18-24 (20.9% vs. 35.8%, 
respectively; p<0.0001), but there were increases in the proportions of White MSM (29.5% 
vs. 18.3%, respectively; p=0.008). The proportion of MSM who reported having received an 
HIV test in the last 12 months significantly increased from 2011 to 2014 (58.8% vs. 71.2%, 
respectively; p=0.0006).
Table 2 displays self-reported awareness, use, and willingness to use PrEP for Washington, 
DC and Miami-Dade County by cycle year. Between 2011 and 2014, there was a significant 
increase in awareness of “people taking ARVs to prevent HIV acquisition” in both 
Washington, DC (39.1% vs. 73.8%, respectively; p<0.0001) and Miami-Dade County 
(19.4% vs. 41.2%, respectively; p<0.0001). Similarly, the reported use of PrEP in the last 12 
months increased in both cities from 2011 to 2014, but was only significant in Washington, 
DC, with an increase in PrEP use from 0% in 2011 to 7.7% in 2014 (p<0.0001). Although 
low, the proportions of MSM reporting they strongly agreed or agreed that they would no 
longer need to use condoms if taking PrEP were significantly higher in both jurisdictions 
between 2011 and 2014 (Washington, DC: 4.7% vs. 8.7%, respectively; p=0.04; Miami-
Dade County: 5.3% vs. 9.8%, respectively; p=0.04).
Univariate and multivariate analyses revealed several differences between 2011 and 2014 in 
both Washington, DC and Miami-Dade County, FL, and results are presented separately by 
city (Table 3).
Washington, DC
In 2011 the characteristics positively associated with being very likely to use PrEP included: 
being younger than 35 years (18-24 years: OR=3.40; 95% CI= 1.78, 6.48; 25-34 years: 
OR=2.04; 95% CI=1.22, 3.39), being Hispanic versus White (OR=3.50; 95% CI= 1.52, 
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8.05), an annual household income <$20,000 compared to $40,000 or more (OR=2.53; 95% 
CI=1.22, 5.21), and infrequent binge drinking (<1/week) vs. never drinks (OR=2.57; 95% 
CI=1.04, 6.37). In the multivariate model, younger MSM (18-24 years old) were more than 
twice as likely (OR=2.28; 95% CI=1.08, 4.84) to report being very likely to use PrEP 
compared to MSM 35 years or older. Hispanic MSM also had higher odds of being very 
likely to use PrEP compared to White MSM (OR=3.85; 95% CI=1.56, 9.51). MSM 
reporting 2-5 male sexual partners in the last 12 months had reduced odds of being very 
likely to use PrEP compared to those with 6 or more partners (OR=0.55; 95% CI=0.31, 
0.95).
In 2014, MSM reporting fewer than 6 male sexual partners (vs. 6+) had decreased odds of 
being very likely to use PrEP (1 partner: OR=0.46; 95% CI=0.23, 0.94; 2-5 partners: 
OR=0.58; 95% CI=0.36, 0.93). When compared to White MSM, Black MSM had higher 
odds of being very likely to use PrEP; although this was not statistically significant, this was 
retained in the overall adjusted model. In 2014, the independent correlates of being very 
likely to use PrEP included being Black (OR=1.80; 95% CI=1.04, 3.13) and having 1 
(OR=0.38; 95% CI=0.18, 0.80) or 2-5 (OR=0.45; 95% CI=0.27, 0.75) compared to 6 or 
more male sexual partners in the last 12 months.
Miami-Dade County
For Miami-Dade County in 2011, there were no significant univariate associations with 
being very likely to use PrEP. Among MSM in Miami-Dade County, independent correlates 
in 2011 included being Hispanic (OR=0.39; 95% CI=0.16, 0.93), reporting non-injection 
drug use in the last 12 months (OR=0.54; 95% CI=0.32, 0.92) and an annual income 
$20,000-$39,999 vs. ≥$40,000 (OR=1.86; 95% CI=1.01, 3.41).
In 2014, being Hispanic (OR=2.13; 95% CI=1.07, 4.24), and newly identified as HIV-
positive (OR=2.83; 95% CI=1.27, 6.30) were associated with being very likely to use PrEP. 
In 2014, being Hispanic (OR=2.19; 95% CI=1.09, 4.41) and newly identified as HIV 
positive (OR=2.87; 95% CI=1.27, 6.50) were associated with increased odds of being very 
likely to use PrEP among MSM.
Discussion
Among community recruited MSM in Washington, DC and Miami-Dade County, FL, 
awareness and use of PrEP increased from 2011 to 2014. In Washington, DC a lower 
proportion of MSM reported being very likely to use PrEP in 2014 vs. 2011, while in 
Miami-Dade County this proportion increased over time. Although awareness of PrEP 
increased over time in both cities, in 2014 more than 70% of MSM in Washington, DC had 
heard of people taking ARVs to prevent HIV acquisition, while only 40% had in Miami-
Dade County. MSM in Miami-Dade similarly reported a lower proportion of PrEP use than 
Washington, DC in both 2011 and 2014. Of note, although the majority of MSM across time 
points in both cities believed they would use condoms and practice safe sex if using PrEP, 
this sentiment decreased over time, suggesting that other protective behaviors may change 
with increased PrEP use, as evidenced by recent reports revealing high rates of STI among 
PrEP users.14,16,29 This may be of concern, given that behavior changes, such as increased 
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condomless sex, may continue even if a person discontinues PrEP use, thus potentially 
resulting in heightened HIV risk over time.
Two years after FDA approval, and nearly four years after release of the iPrEX study results, 
PrEP use was low in both cities. In 2014, PrEP use among MSM in Miami-Dade County 
was similar to internet-recruited MSM residing in rural areas19 and in San Francisco prior to 
the release of iPrEX data,30 while Washington, DC was comparable to internet-recruited 
MSM from Los Angeles and Chicago between 2014 and 2015.19 Although PrEP use in both 
cities was low compared to some recent findings among samples of high-risk MSM20,24, our 
sample was not limited to MSM exhibiting high-risk behaviors, and thus might be expected 
to be lower. Slow uptake even with increased awareness in both jurisdictions, may be related 
to stigma associated with being assumed HIV positive or being labeled “high-risk” as result 
of using PrEP.31 The U.S. PrEP Demonstration project found that overall uptake of PrEP 
was high when offered in STD clinics and a community health center, and that participants 
from Miami or Washington, DC and those who reported previous knowledge of PrEP were 
more likely to enroll.32 These findings indicate the potential for future increases in PrEP use 
as both cities expand access to and promotion of PrEP.
While other studies have seen slight increases over time in willingness to use PrEP, 19,24 our 
study found substantial changes in being willing to use PrEP in both cities. The direction of 
this change varied, with a lower proportion of MSM in Washington, DC and a higher 
proportion of MSM in Miami-Dade County to report being very likely to use PrEP in 2014 
vs. 2011. These differences may be related to the level of awareness around PrEP in each 
city, since less than 50% of MSM in Miami had heard of PrEP in 2014 compared to over 
70% in Washington, DC. Between 2011 and 2014, both Miami-Dade County and 
Washington, DC were sites for the U.S. PrEP Demonstration Project, which similarly found 
that participants in Miami-Dade County reported lower PrEP awareness than those in 
Washington, DC.32 In addition, Washington, DC was also a site for HPTN 06933 and HPTN 
073.34 The presence of more PrEP trials before and during data collection in 2014, may 
partially explain the higher level of awareness of PrEP in Washington, DC relative to Miami-
Dade County.
The results of this this study should be considered in the context of its limitations. These 
samples were recruited using VBS; thus these results may not be generalizable to non-venue 
attending MSM. These data were not weighted to account for variation in venue attendance 
or likelihood of being selected, which may have also result in the decreased ability to 
generalize behaviors across men who do attend venues. This study is based on self-report 
data which may be affected by recall or social desirability bias, but this is appropriate to 
outcome measures which include perceptions and are otherwise unmeasurable. Although 
interviewers were highly trained and routine data quality checks were conducted, there was 
the possibility of recording errors and intra/inter-interviewer differences in administration. 
Additionally, increases in awareness and uptake in 2014 may be driven by local PrEP 
demonstration projects that had already been launched in these respective municipalities, 
and therefore these data may actually reflect the effects of local public health programming. 
Lastly, due to data sharing restrictions, we were unable to conduct between city analyses.
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To our knowledge, this is one of the first studies to examine degree of willingness to use 
PrEP among community-recruited MSM over time, prior to large scale public health efforts 
in each city to increase PrEP uptake.35,36 Our findings show that although awareness of 
PrEP may be increasing, use among MSM in Washington, DC and Miami-Dade County 
remains low. Geographic difference in willingness to use PrEP between 2011 and 2014 
highlight the need for regionally tailored PrEP information and behavioral interventions to 
increase willingness and use among MSM. With the expansion of PrEP services in both 
jurisdictions, access to PrEP should be explored in future analyses.
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